{"analyses":[{"ciLowerLimit":"46.2","ciPctValue":"95","ciUpperLimit":"79.2","groupIds":["OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percentage of participants","paramValue":"63.9","testedNonInferiority":false},{"ciLowerLimit":"45.1","ciPctValue":"95","ciUpperLimit":"79.6","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percentage of participants","paramValue":"63.6","testedNonInferiority":false},{"ciLowerLimit":"21.5","ciPctValue":"95","ciUpperLimit":"55.1","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percentage of participants","paramValue":"37.1","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"description":"Urinary N-telopeptide (uNTX) corrected by creatinine \\< 50 nmol/mmol at week 25.","groups":[{"description":"Open-label intravenous (IV) bisphosphonate once every 4 weeks (Q4W)","id":"OG000","title":"Bisphosphonate IV Q4W"},{"description":"Open-label denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W)","id":"OG001","title":"Denosumab 180 mg Q12W"},{"description":"Open-label denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W)","id":"OG002","title":"Denosumab 180 mg Q4W"}],"paramType":"NUMBER","populationDescription":"All participants who are randomized to the treatment phase, receive at least one dose of treatment phase investigational product, and have treatment phase baseline measurements of uNTx and at least one treatment phase post-baseline measurement of uNTx.","reportingStatus":"POSTED","timeFrame":"25 weeks","title":"uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 25","type":"SECONDARY","unitOfMeasure":"Participants"}